Aktuellt
SENASTE
Redeye is a bit surprised by the swift change of CEO in IRLAB, which came shortly after the missed primary endpoint in the phase IIb trial with Mesdopetam, that led the share price to drop by some 70%. Gunnar Olsson, the current chairman, has been appointed interim CEO and Carola Lemne will take on the role as chairman. We speculate that the role for the incoming CEO will be a bit more focused on business development/financing and navigating the company through these more uncertain times. We will return with a more thorough comment in relation to our Q4 update.
LÄS MER
